Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 8721 - 8728 of 12143 results

Mintz Launches Sports-Focused Practice Group
February 2, 2016| News

Provider Consolidation: Prescription for Surviving Antitrust Investigations
February 2, 2016| News

Preparation for 2015 Fiscal Year-End SEC Filings and 2016 Annual Shareholder Meetings
February 2, 2016| Advisory| Viewpoint

DOL Issues Guidance on Joint Employment
February 1, 2016| Blog| Viewpoint

Governor Baker Files FY2017 Budget, Economic Development Bill; Speaker DeLeo Outlines Agenda
February 1, 2016| Alert| Viewpoint

FDA Releases Draft Guidance for Medical Device Cybersecurity
February 1, 2016| Blog| Viewpoint

Inphi v. Netlist: Alternative Features Satisfy the Patent Written Description Requirement for a Negative Claim Limitation
February 1, 2016| Blog| Viewpoint

Pfizer v. Lee: A Patent Term Adjustment Double Standard?
February 1, 2016| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
